MCID: PNC034
MIFTS: 48

Pancreas Disease

Categories: Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Pancreas Disease

Summaries for Pancreas Disease

Disease Ontology : 12 An endocrine system disease that is located in the pancreas.

MalaCards based summary : Pancreas Disease, also known as pancreatic diseases, is related to non-alcoholic fatty liver disease and pancreatic cancer, and has symptoms including nausea and vomiting, abdominal pain and constipation. An important gene associated with Pancreas Disease is MIR21 (MicroRNA 21), and among its related pathways/superpathways are MicroRNAs in cancer and Cell Differentiation - Index. The drugs Esomeprazole and Propofol have been mentioned in the context of this disorder. Affiliated tissues include pancreas, testes and liver.

Wikipedia : 74 The pancreas is an organ of the digestive system and endocrine system of vertebrates. In humans, it is... more...

Related Diseases for Pancreas Disease

Diseases related to Pancreas Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 297)
# Related Disease Score Top Affiliating Genes
1 non-alcoholic fatty liver disease 31.4 MIR34A MIR31 MIR30A MIR21 MIR199A1 MIR17
2 pancreatic cancer 31.2 SERPINA3 MIR483 MIR34A MIR31 MIR30A MIR221
3 lipid metabolism disorder 31.1 MIR21 MIR126 INS H2AC18
4 non-alcoholic steatohepatitis 30.6 MIR34A MIR21 INS
5 pancreatic adenocarcinoma 30.4 MIR221 MIR21 MIR196A1 MIR155 INS
6 alcohol use disorder 30.3 MIR199A1 H2AC18 CCR6
7 endocrine pancreas disease 12.2
8 pancreas, annular 11.0
9 pancreatic agenesis 11.0
10 intestinal benign neoplasm 10.9 SERPINA3 MIR483 MIR21 MIR199A1 MIR196A1 MIR17
11 bacterial infectious disease 10.9 SERPINA3 MIR155 H2AC18 CCR6
12 bone sarcoma 10.9 SERPINA3 MIR9-1 MIR31 MIR21 MIR199A1 MIR17
13 autoimmune disease of musculoskeletal system 10.9 SERPINA3 MIR30A MIR21 MIR196A1 MIR155 MIR142
14 pleural disease 10.9 SERPINA3 MIR199A1 MIR17 MIR125A H2AC18 CCR6
15 extrinsic cardiomyopathy 10.9 SERPINA3 MIR21 MIR199A1 MIR142 H2AC18 CCR6
16 tongue disease 10.9 MIR486-1 MIR483 MIR31 MIR30A MIR21 MIR199A1
17 lipid storage disease 10.9 SERPINA3 MIR483 MIR21 MIR199A1 MIR155 MIR142
18 coronavirus infectious disease 10.9 SERPINA3 MIR17 H2AC18 CCR6
19 bone resorption disease 10.9 SERPINA3 MIR199A1 MIR196A1 MIR142 INS H2AC18
20 thyroid gland disease 10.9 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR17 MIR142
21 pre-malignant neoplasm 10.9 SERPINA3 MIR17 MIR142 H2AC18 CCR6
22 heart valve disease 10.9 SERPINA3 MIR486-1 MIR21 MIR199A1 MIR17 MIR126
23 ovary epithelial cancer 10.9 SERPINA3 MIR9-1 MIR483 MIR30A MIR21 MIR199A1
24 malignant ovarian surface epithelial-stromal neoplasm 10.9 SERPINA3 MIR9-1 MIR483 MIR30A MIR21 MIR199A1
25 gastrointestinal system benign neoplasm 10.9 SERPINA3 MIR483 MIR30A MIR21 MIR199A1 MIR196A1
26 polymyositis 10.9 MIR30A MIR221 MIR21 MIR155
27 vascular disease 10.9 MIR221 MIR21 MIR199A1 MIR126 MIR125A INS
28 muscular disease 10.9 SERPINA3 MIR9-1 MIR221 MIR199A1 MIR196A1 MIR142
29 primary bacterial infectious disease 10.9 SERPINA3 MIR21 MIR155 MIR142 MIR125A H2AC18
30 parasitic helminthiasis infectious disease 10.9 SERPINA3 MIR21 H2AC18 CCR6
31 bone cancer 10.9 SERPINA3 MIR9-1 MIR31 MIR21 MIR199A1 MIR196A1
32 retinal vascular disease 10.9 MIR30A MIR21 MIR199A1 MIR126 INS H2AC18
33 substance abuse 10.9 SERPINA3 MIR199A1 INS H2AC18 CCR6
34 muscle cancer 10.9 SERPINA3 MIR9-1 MIR199A1 MIR196A1 MIR142 H2AC18
35 bronchial disease 10.9 SERPINA3 MIR21 MIR17 MIR155 MIR142 MIR126
36 gallbladder disease 10.9 SERPINA3 MIR483 MIR199A1 MIR196A1 MIR17 MIR126
37 skin disease 10.9 SERPINA3 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
38 bone remodeling disease 10.8 SERPINA3 MIR199A1 MIR142 INS H2AC18 CCR6
39 aortic disease 10.8 SERPINA3 MIR486-1 MIR21 MIR199A1 MIR17 MIR126
40 infratentorial cancer 10.8 MIR9-1 MIR199A1 MIR196A1 MIR17 MIR142 H2AC18
41 uveal disease 10.8 SERPINA3 MIR9-1 MIR199A1 MIR142 MIR125A H2AC18
42 lysosomal storage disease 10.8 SERPINA3 MIR21 MIR199A1 MIR155 INS H2AC18
43 autoimmune disease of endocrine system 10.8 MIR142 MIR125A INS H2AC18 CCR6
44 leukocyte disease 10.8 SERPINA3 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
45 in situ carcinoma 10.8 SERPINA3 MIR17 MIR142 MIR126 H2AC18
46 pulmonary disease, chronic obstructive 10.8 SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR126
47 ovarian serous carcinoma 10.8 MIR21 MIR199A1 MIR125A MIR10B
48 retinal cancer 10.8 MIR9-1 MIR486-1 MIR483 MIR199A1 MIR196A1 MIR17
49 acute cystitis 10.8 SERPINA3 INS H2AC18 CCR6
50 testicular disease 10.8 SERPINA3 MIR199A1 H2AC18 CCR6

Graphical network of the top 20 diseases related to Pancreas Disease:



Diseases related to Pancreas Disease

Symptoms & Phenotypes for Pancreas Disease

UMLS symptoms related to Pancreas Disease:


nausea and vomiting, abdominal pain, constipation, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas, digestive system symptom

Drugs & Therapeutics for Pancreas Disease

Drugs for Pancreas Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
2
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
4
Remifentanil Approved Phase 4 132875-61-7 60815
5
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Rebamipide Investigational Phase 4 90098-04-7
8 Gastrointestinal Agents Phase 4
9 Proton Pump Inhibitors Phase 4
10 Antacids Phase 4
11 Anti-Ulcer Agents Phase 4
12 Hypnotics and Sedatives Phase 4
13 Pharmaceutical Solutions Phase 4
14 Analgesics Phase 4
15 Analgesics, Non-Narcotic Phase 4
16 Antipyretics Phase 4
17
Ivacaftor Approved Phase 3 873054-44-5 16220172
18
Scopolamine Approved, Investigational Phase 3 6533-68-2, 51-34-3 5184
19
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
20
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
21
Tazobactam Approved Phase 3 89786-04-9 123630
22
Cefoxitin Approved Phase 3 35607-66-0 441199
23
Cefotaxime Approved Phase 3 63527-52-6 5742673 456256
24
Piperacillin Approved Phase 3 66258-76-2 43672
25
Sufentanil Approved, Investigational Phase 2, Phase 3 56030-54-7 41693
26
Ropivacaine Approved Phase 2, Phase 3 84057-95-4 71273 175805
27
Bupivacaine Approved, Investigational Phase 2, Phase 3 2180-92-9, 38396-39-3 2474
28
Sevoflurane Approved, Vet_approved Phase 2, Phase 3 28523-86-6 5206
29
Somatostatin Approved, Investigational Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
30
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
31
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
32
Methionine Approved, Nutraceutical Phase 3 63-68-3 6137
33
Beta carotene Approved, Nutraceutical Phase 3 7235-40-7
34 Tocotrienol Investigational Phase 3 6829-55-6
35 Liver Extracts Phase 3
36 Neurotransmitter Agents Phase 3
37 Cholinergic Agents Phase 3
38 Parasympatholytics Phase 3
39 Drotaverin Phase 3
40 Vasodilator Agents Phase 3
41 Antiemetics Phase 3
42 Muscarinic Antagonists Phase 3
43 Cholinergic Antagonists Phase 3
44 Bromides Phase 3
45 Mydriatics Phase 3
46 Butylscopolammonium Bromide Phase 3
47 Antioxidants Phase 3
48 Vitamins Phase 3
49 Protective Agents Phase 3
50 Carotenoids Phase 3

Interventional clinical trials:

(show top 50) (show all 115)
# Name Status NCT ID Phase Drugs
1 Prevention for Surgical Site Infection After Pancreatic Resection Unknown status NCT00661648 Phase 4
2 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
3 Alfentanil vs Remifentanil in Patient-controlled Sedation During ERCP.A Randomized Double-blind Study Completed NCT01350037 Phase 4 alfentanil;remifentanil
4 Randomized Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy Completed NCT00526331 Phase 4
5 A Prospective Multi-center Randomized Study of the Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
6 Role of Scheduled Intravenous Acetaminophen for Postoperative Pain Management in an Enhanced Recovery After Surgery (ERAS) Population: A Prospective, Randomized, Double-Blind and Placebo-Controlled Clinical Trial Active, not recruiting NCT03198871 Phase 4 Acetaminophen Injectable Product;Sodium Chloride 0.9%, Intravenous
7 A Placebo Controlled, Double-Blind, Parallel, Multicenter Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers Completed NCT01087801 Phase 3 ChiRhoStim;Placebo
8 Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During ERCP: a Prospective, Multicenter Randomized Controlled Trial Completed NCT00731198 Phase 3 Drotaverine hydrochloride;Hyoscine-N-butylbromide
9 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects With Cystic Fibrosis and the G551D Mutation Completed NCT00909532 Phase 3 Ivacaftor;Placebo
10 A Phase 3, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX-770 in Subjects Aged 6 to 11 Years With Cystic Fibrosis and the G551D Mutation Completed NCT00909727 Phase 3 Ivacaftor;Placebo
11 Phase III Study of Efficacy of Remote Ischemic Preconditioning in Improving Outcomes in Organ Transplantation Completed NCT00975702 Phase 3
12 Effect of Antioxidant Supplementation on Pain, Antioxidant Profile and Oxidative Stress in Patients With Chronic Pancreatitis Completed NCT00319358 Phase 3
13 A Phase III Multicenter, Open Label Randomized Controlled Trial of Cefoxitin Versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy Recruiting NCT03269994 Phase 3 Cefoxitin;Piperacillin-tazobactam
14 The Impact of an Epidural Anesthetic on the Consumption of Sevoflurane in Major Abdominal Surgery Recruiting NCT04021264 Phase 2, Phase 3 Ropivacaine-Sufentanil;Dextrose 5
15 A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma Active, not recruiting NCT01964430 Phase 3 nab-Paclitaxel;Gemcitabine
16 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
17 Saline Hypertonic in Preschoolers With Cystic Fibrosis and Lung Structure as Measured by Computed Tomography (CT) Active, not recruiting NCT02950883 Phase 2, Phase 3 Active Treatment Group 7% Hypertonic Saline;Control Group 0.9% Isotonic Saline
18 Randomized Control Trial Comparing Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics Enrolling by invitation NCT04329039 Phase 2, Phase 3 Somatostatin analog
19 A Proof-of-Concept, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme® Unknown status NCT02722122 Phase 2 AIR DNase™
20 A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of VX-809 to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects Homozygous for the ∆F508-CFTR Gene Mutation Completed NCT00865904 Phase 2 VX-809;Placebo
21 An Open-Label Phase 2 Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 Completed NCT01608711 Phase 2
22 A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer Completed NCT00902291 Phase 2
23 A Phase II Study of Gemcitabine and Nab-Paclitaxel in Combination With GDC-0449 (Hedgehog Inhibitor) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas Completed NCT01088815 Phase 2 Gemcitabine, nab-Paclitaxel, GDC-0449
24 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of VX-770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis (CF) Subjects With Genotype G551D Completed NCT00457821 Phase 2 Ivacaftor 25 mg/75 mg;Ivacaftor 75 mg/150 mg;Ivacaftor 150 mg or 250 mg;Placebo
25 A Phase I/II Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Combination in Metastatic Pancreatic Cancer Recruiting NCT03535727 Phase 1, Phase 2 Nab-paclitaxel;Gemcitabine;Capecitabine;Cisplatin;Irinotecan;Nab-paclitaxel;Gemcitabine;Capecitabine;Cisplatin;Irinotecan
26 Evaluation of the Effect of Ocoxin-Viusid® Nutritional Supplement in the Life Quality in Patients Diagnosed With Advanced Pancreatic Adenocarcinoma. Phase II Recruiting NCT03717298 Phase 2
27 A Trial Evaluating Escalating Doses and the Safety of Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms Recruiting NCT03188991 Phase 2 NanoPac®
28 Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma Recruiting NCT03077685 Phase 2 NanoPac®
29 A Single-arm Phase II Trial of Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy Active, not recruiting NCT03410914 Phase 2
30 Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED) Terminated NCT00040131 Phase 2 IL-10
31 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of VX-770 in Subjects Aged 12 Years and Older With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Terminated NCT00953706 Phase 2 Ivacaftor;Placebo
32 Phase II, Open Label Study of Intravenous Ascorbic Acid in Combination With Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer Terminated NCT01555489 Phase 2 Ascorbic Acid
33 A Phase I/II Study of Sunitinib and Dacarbazine in Patients With Metastatic Melanoma Terminated NCT00496223 Phase 1, Phase 2 Sunitinib;Dacarbazine
34 A Multicenter Phase II Open Study Coupled With a Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Poorly-differentiated Advanced/Inoperable NEURO-Endocrine Tumors. Terminated NCT01215578 Phase 2 Sutent
35 Phase 1/2 Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma. Terminated NCT01431794 Phase 1, Phase 2 LDE225-600mg;Gemcitabine;nab-paclitaxel;LDE225-400mg;LDE225-800mg
36 A Randomised, Double-blind, Placebo-controlled Dose-escalation Phase I Study to Evaluate the Safety and Tolerability of Inhaled Aerosolised OligoG CF-5/20 (G-block Oligosaccharide Derived From Alginate Polysaccharide) in Healthy Volunteers Completed NCT00970346 Phase 1 OligoG CF-5/20
37 89Zr-MMOT0530A PET Imaging in Patients With Unresectable Pancreatic or Platinum-resistant Ovarian Cancer Before Treatment With DMOT4039A. A Separate Study to the Phase I Study Protocol DMO4993g Completed NCT01832116 Phase 1 89Zr-MMOT0530A
38 A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02231723 Phase 1 BBI608;Nab-paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Irinotecan;Fluorouracil;MM-398
39 RG1068 (Synthetic Human Secretin) Enhanced Multidetector CT Pancreatography: Evaluation of the Pancreatic Duct in Patients With Known or Suspected Chronic Pancreatitis Terminated NCT00620919 Phase 1 RG1068 (Synthetic Human Secretin)
40 Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Unknown status NCT01427712
41 Zhujiang Hospital of the Southern Medical University Unknown status NCT03074708
42 Indications and Outcomes of Gastrointestinal Endoscopic Ultrasound in Tanta-Egypt: Initial Experience. Unknown status NCT03267355
43 A Network on the Quality of ERCP, on the Organization of the Endoscopic Units and on the Training of the Endoscopists in Italy Unknown status NCT02971579
44 Effectiveness of Metal Protheses Covered in "Diabolo" in Treatment of Necrosis of Origin Pancreatic: Trial "DIABOLOPIG" Unknown status NCT02739074
45 Cell-free DNA Promoter Hypermethylation in Plasma From Patients With Pancreatic Adenocarcinoma, Compared to Patients With Pancreatitis and Pancreatitis and Patients Screened for, But Not Having Pancreatic Adenocarcinoma." Unknown status NCT02079363
46 Comparative Study Between Minimally Invasive Pancreatico-duodenectomy and Open Pancreatico-duodenectomy for Periampullary Tumors Unknown status NCT02807701
47 Benefit of Tight Glycemic Control in Surgical Patients: Prospective Randomized Clinical Trial Unknown status NCT00735228
48 The Natural History of Chronic Pancreatitis: A Multicenter Study Unknown status NCT03324698
49 The Effect of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide on the Complications After Pancreatectomy. A Prospective, Multicenter Clinical Trial Unknown status NCT03398941 Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide
50 Comparison Between Continuous Infusion and Intermittent Bolus Injection of Propofol for Deep Sedation During Endoscopic Retrograde Cholangiopancreatography: a Prospective Randomized Controlled Study Unknown status NCT01900938 Midazolam;Propofol

Search NIH Clinical Center for Pancreas Disease

Genetic Tests for Pancreas Disease

Anatomical Context for Pancreas Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreas Disease:

19
Pancreas

MalaCards organs/tissues related to Pancreas Disease:

40
Pancreas, Testes, Liver, Kidney, Spleen, Heart, Lung

Publications for Pancreas Disease

Articles related to Pancreas Disease:

(show top 50) (show all 2534)
# Title Authors PMID Year
1
The Use of Values WNR and GNR to Distinguish between and Diagnose Different Types of Pancreatitis. 61
32548210 2020
2
Leukocytosis after distal pancreatectomy and splenectomy as a marker of major complication. 61
31848020 2020
3
Pancreas divisum inversus. 61
31576611 2020
4
Early oral vs parenteral nutrition in acute pancreatitis: a retrospective analysis of clinical outcomes and hospital costs from a tertiary care referral center. 61
31620978 2020
5
Improving the Slice Interaction of 2.5D CNN for Automatic Pancreas Segmentation. 61
32502278 2020
6
[Indications for the Surgical Management of Pancreatic Cystic Lesions]. 61
32498095 2020
7
New-Onset Diabetes Mellitus After Distal Pancreatectomy: A Systematic Review and Meta-analysis. 61
32559393 2020
8
Hepatic subcapsular hematoma post-ERCP: Case report and literature review. 61
32544833 2020
9
Outcome of interventional radiology for delayed postoperative hemorrhage in hepatobiliary and pancreatic surgery. 61
32525234 2020
10
EUS-guided needle biopsy for autoimmune pancreatitis. 61
32519311 2020
11
Abstinent patients with alcohol use disorders show an altered plasma cytokine profile: Identification of both interleukin 6 and interleukin 17A as potential biomarkers of consumption and comorbid liver and pancreatic diseases. 61
32536325 2020
12
Contrast Harmonic Endoscopic Ultrasound in Pancreatic Diseases. 61
32549524 2020
13
Guidelines on the histopathology of chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and the European Pancreatic Club. 61
32414657 2020
14
Identification of genetic loci associated with higher resistance to pancreas disease (PD) in Atlantic salmon (Salmo salar L.). 61
32493246 2020
15
Telomerase reactivation is associated with hepatobiliary and pancreatic cancers. 61
32386990 2020
16
Probe-based confocal laser endomicroscopy for the diagnosis of pancreatic ductal structures. 61
32433791 2020
17
Endoscopic management of pancreatic diseases in patients with surgically altered anatomy: clinical outcomes of combination of double-balloon endoscopy- and endoscopic ultrasound-guided interventions. 61
32434287 2020
18
Fibroblasts from distinct pancreatic pathologies exhibit disease-specific properties. 61
32393661 2020
19
Histopathological findings and canine pancreatic lipase immunoreactivity in normal dogs and dogs with inflammatory and neoplastic diseases of the pancreas. 61
32379386 2020
20
SARS-CoV2 RNA detection in a pancreatic pseudocyst sample. 61
32498972 2020
21
18F-FDG PET/CT and 68Ga-DOTATOC PET/CT in Diffuse Pancreatic Neuroendocrine Tumor. 61
32049733 2020
22
Contacts with Health Services During the Year Prior to Suicide Death and Prevalent Conditions A Nationwide Study. 61
32469801 2020
23
Endoscopic ultrasonography elastography in the diagnosis of intrapancreatic ectopic spleen: A case report. 61
32420307 2020
24
Melatonin modulates proliferation of pancreatic stellate cells through caspase-3 activation and changes in cyclin A and D expression. 61
32361979 2020
25
A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. 61
32486461 2020
26
Pancreatic resections in elderly patients with high American Society of Anesthesiologists' risk score: a view from a tertiary care center. 61
31347102 2020
27
Clinical importance of main pancreatic duct variants and possible correlation with pancreatic diseases. 61
32393143 2020
28
[Treatment of pancreatic diseases and prevention of infection during outbreak of 2019 coronavirus disease]. 61
32107909 2020
29
Endosonography-guided Radiofrequency Ablation in Pancreatic Diseases: Time to Fill the Gap Between Evidence and Enthusiasm. 61
32482951 2020
30
[Obesity and Pancreatobiliary Disease]. 61
32448855 2020
31
Non-occlusive Mesenteric Ischemia as a Fatal Complication in Acute Pancreatitis: A Case Series. 61
31529415 2020
32
Lipocalin-2 expression and function in pancreatic diseases. 61
31932215 2020
33
Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells. 61
32019781 2020
34
Laparoscopic versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a single-center propensity score matching study. 61
32266660 2020
35
Serum levels of advanced glycation end products and their receptors sRAGE and Galectin-3 in chronic pancreatitis. 61
31870801 2020
36
Molecular and genetic regulation of pig pancreatic islet cell development. 61
32108026 2020
37
Promoter DNA Hypermethylation of the Cysteine Dioxygenase 1 (CDO1) Gene in Intraductal Papillary Mucinous Neoplasm (IPMN). 61
32144623 2020
38
Secretin-Stimulated Magnetic Resonance Imaging Reveals Variable Diagnostic Accuracy According to Etiology in Pancreatic Disease. 61
32132505 2020
39
Men1 maintains exocrine pancreas homeostasis in response to inflammation and oncogenic stress. 61
32156729 2020
40
Radioguided surgery with β- radiation in pancreatic Neuroendocrine Tumors: a feasibility study. 61
32132632 2020
41
Acute Pancreatitis: Exploring Nutrition Implications. 61
32181949 2020
42
Robotic spleen-preserving distal pancreatectomy: the Verona experience. 61
32162271 2020
43
The utility of digital cholangioscopy (SpyGlass DS) in biliary and pancreatic diseases: A clinical feasibility study at two tertiary care centers in Saudi Arabia (with Videos). 61
32179048 2020
44
The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer. 61
30080738 2020
45
Novel Autoantibody Signatures in Sera of Patients with Pancreatic Cancer, Chronic Pancreatitis and Autoimmune Pancreatitis: A Protein Microarray Profiling Approach. 61
32244327 2020
46
History of pancreatic surgery in Japan: Respect to the Japanese pioneers of pancreatic surgery. 61
32258976 2020
47
Prevalence Rate and Predictive Factors of Pancreatic Diseases in Cases with Pancreatic Duct Dilatation: A Cross-sectional Study of a Large, Healthy Japanese Population. 61
31813913 2020
48
Inflammatory bowel disease and pancreatic diseases. 61
32283880 2020
49
Clinical Application of Metabolomics in Pancreatic Diseases: A Mini-Review. 61
31340007 2020
50
Performance of deep learning for differentiating pancreatic diseases on contrast-enhanced magnetic resonance imaging: A preliminary study. 61
31375430 2020

Variations for Pancreas Disease

Expression for Pancreas Disease

Search GEO for disease gene expression data for Pancreas Disease.

Pathways for Pancreas Disease

Pathways related to Pancreas Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.93 MIR9-1 MIR483 MIR34A MIR31 MIR30A MIR221
2 10.71 MIR9-1 MIR221 MIR199A1

GO Terms for Pancreas Disease

Cellular components related to Pancreas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 9.5 MIR34A MIR30A MIR221 MIR21 MIR17 MIR126
2 extracellular space GO:0005615 9.47 SERPINA3 MIR486-1 MIR31 MIR30A MIR221 MIR21

Biological processes related to Pancreas Disease according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.02 MIR34A MIR30A MIR21 MIR155 MIR125A INS
2 negative regulation of gene expression GO:0010629 9.96 MIR21 MIR17 MIR155 MIR125A
3 positive regulation of protein kinase B signaling GO:0051897 9.91 MIR221 MIR21 MIR199A1 MIR126 INS
4 cellular response to hypoxia GO:0071456 9.88 MIR34A MIR17 MIR155 MIR126
5 positive regulation of angiogenesis GO:0045766 9.88 MIR31 MIR30A MIR21 MIR199A1 MIR126
6 positive regulation of inflammatory response GO:0050729 9.83 MIR21 MIR155 MIR126
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.82 MIR21 MIR126 INS
8 negative regulation of inflammatory response GO:0050728 9.8 MIR31 MIR221 MIR155 MIR142 MIR126
9 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.78 MIR221 MIR21 MIR17
10 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.76 MIR31 MIR126 MIR10B
11 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.74 MIR221 MIR155 MIR125A
12 negative regulation of sprouting angiogenesis GO:1903671 9.73 MIR34A MIR221 MIR17
13 positive regulation of blood vessel endothelial cell migration GO:0043536 9.73 MIR31 MIR30A MIR221 MIR126
14 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.71 MIR21 MIR126 MIR10B
15 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.7 MIR199A1 MIR17 MIR155
16 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.67 MIR21 INS
17 negative regulation of JAK-STAT cascade GO:0046426 9.67 MIR9-1 MIR155
18 positive regulation of connective tissue replacement GO:1905205 9.67 MIR34A MIR199A1 MIR155
19 negative regulation of vascular endothelial growth factor production GO:1904046 9.67 MIR34A MIR199A1 MIR17 MIR125A
20 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.66 MIR17 MIR155
21 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.65 MIR21 MIR125A
22 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.65 MIR483 MIR221 MIR199A1 MIR196A1 MIR155
23 positive regulation of microglial cell activation GO:1903980 9.64 MIR155 MIR142
24 negative regulation of cell adhesion molecule production GO:0060354 9.64 MIR221 MIR155
25 positive regulation of metalloendopeptidase activity GO:1904685 9.63 MIR21 MIR17
26 negative regulation by host of viral genome replication GO:0044828 9.63 MIR221 MIR155
27 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.63 MIR199A1 MIR17 MIR155
28 negative regulation of vascular wound healing GO:0061044 9.62 MIR34A MIR155
29 negative regulation of regulatory T cell differentiation GO:0045590 9.62 MIR21 MIR155
30 positive regulation of sprouting angiogenesis GO:1903672 9.62 MIR31 MIR155 MIR126 MIR125A
31 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.61 MIR21 MIR17
32 negative regulation of interleukin-21 biosynthetic process GO:0045391 9.6 MIR221 MIR21
33 negative regulation of interleukin-21 production GO:0032705 9.59 MIR221 MIR21
34 miRNA mediated inhibition of translation GO:0035278 9.56 MIR9-1 MIR483 MIR31 MIR30A MIR221 MIR21
35 gene silencing by miRNA GO:0035195 9.53 MIR9-1 MIR486-1 MIR483 MIR34A MIR31 MIR30A
36 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.46 MIR31 MIR221 MIR155 MIR125A

Molecular functions related to Pancreas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.5 MIR9-1 MIR483 MIR34A MIR31 MIR30A MIR221

Sources for Pancreas Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....